Ziegler R, Uhl K, Minne H, Russmann D, Döring B
Urologe A. 1980 Jul;19(4):226-30.
In patients with recurrent idiopathic nephrolithiasis we studied whether treatment with sodium cellulose phosphate leading to decreased intestinal calcium absorption could induce secondary hyperparathyroidism and whether thiazides which diminish calciuria would impair glucose tolerance. After removal of a actual kidney stone, 74 patients were treated for one year as follows: 25 (group 1) received conventional therapy (Nieron), 22 (group 2) received sodium cellulose phosphate, and 27 (group 3) received sodium cellulose phosphate plus hydrochlorothiazide. The period of one year was too short to evaluate the effectiveness of treatment regarding stone recurrence, however, a significant decrease in calciuria only was seen in group 3. With respect to the possibility to develop secondary hyperparathyroidism, group 2 and group 3 did not reveal any hints. In group 3, the thiazide treatment did not worsen glucose tolerance. Therefore, longer lasting studies with these drugs could be performed without evident danger to develop the mentioned side effects.
在复发性特发性肾结石患者中，我们研究了使用导致肠道钙吸收减少的磷酸纤维素钠治疗是否会诱发继发性甲状旁腺功能亢进，以及减少尿钙的噻嗪类药物是否会损害糖耐量。在取出实际的肾结石后，74例患者接受了为期一年的如下治疗：25例（第1组）接受常规治疗（尼伦），22例（第2组）接受磷酸纤维素钠治疗，27例（第3组）接受磷酸纤维素钠加氢氯噻嗪治疗。一年的时间太短，无法评估治疗对结石复发的有效性，然而，仅在第3组中观察到尿钙显著降低。关于发生继发性甲状旁腺功能亢进的可能性，第2组和第3组未显示任何迹象。在第3组中，噻嗪类药物治疗并未使糖耐量恶化。因此，可以对这些药物进行更长期的研究，而不会有明显出现上述副作用的风险。
